Low back pain is counting among the diseases which cause most devastation in a person's life. About 23% of the population suffering from low back pain. Out of which, 11%–12% population exhibit disability due to severe pain. The management of low back pain involves various modalities; pharmacological as well as non-pharmacological. One section of doctors prefer pharmacological approaches like steroids, NSAIDs, neurotropic, opioid or surgery, While other choose non-pharmacological approaches as these associated with lesser adverse effects.
The analysis discovers moderate – quality evidence regarding manipulation and mobilization therapies role in lessening pain and disability with complete safety.
There is moderate-to high-quality evidence that anticonvulsants are ineffective for the treatment of low back pain or lumbar radicular pain. There is high-quality evidence that gabapentinoids have a higher risk of adverse events.
Globally, millions of people are suffered from low back pain (LBP) and become a major cause of disability than any other health complication. It is predicted that about 5% to 10% of patients with LBP have sciatica and followed by leg pain.
There were no significant differences in the primary outcomes and change in Health Assessment Questionnaire (HAQ), although the mean change in modified Total Sharp Score (mTSS) was 0.25 units (95 % CI, 0.01 to 0.49; P=0.04) higher in low-dose group at week 52. The author observed no significant difference in the median reduction in IgG levels between the study group.
We have previously published a systematic review and meta-analysis (SRMA) comparing low- versus high-dose rituximab (RTX) for the treatment of rheumatoid arthritis (RA), which showed no significant differences in primary efficacy outcomes between the two RTX schemes.
Puerarin injection was effective for the treatment of diabetic peripheral neuropathy by improving the total effective rate, nerve conduction velocity that was decreased by diabetes, and improve the hemorheology index and also relatively safe clinically.
Diabetic peripheral neuropathy (DPN) is one of the most common neuropathies caused by diabetes mellitus (DM), with prevalence of 30-90%.
Acetyl-L-Carnitine (ALC) has a moderate effect in reducing pain on peripheral neuropathic pain (PNP) patients with acceptable safety. After treatment of ALC in diabetic subgroup presented a significant decreased in Visual Analogue Scale (VAS) scores and less significant reduction in VAS scores was observed in non-diabetic group compared with those receiving placebo.
Peripheral neuropathic pain (PNP) leads to an unpleasant experience due to lesion of peripheral nerves, which may be a result of a complication of diabetes mellitus, drug adverse effect, or other origins.